Cardiff Lexington Corporation Reports Significant Financial Decline in Q2 and First Half of 2026

Cardiff Lexington Corporation reported a significant decline in financial performance for the second quarter and first half of 2026, as detailed in its latest 10-Q filing. For the three months ended June 30, 2026, the company generated revenue of $2.16 million, a decrease of 22.6% from $2.79 million in the same period of 2025. The decline in revenue was attributed to a lower realization rate on patient case claim settlements, which fell to 41% from 43% year-over-year, despite a slight increase in patient visits and billed procedures. The cost of sales also decreased to $977,242, but as a percentage of revenue, it rose to 45.3%, reflecting the impact of reduced revenue on fixed costs.

The company's net loss for the second quarter was $2.48 million, compared to a loss of $1.23 million in the prior year, marking an increase in losses of over 102%. This was driven by a substantial rise in operating expenses, which totaled $1.73 million, up from $1.09 million in the previous year. Notably, share-based compensation expenses surged to $366,939 from $97,500, contributing to the overall increase in operating costs. The total loss from operations was $544,643, a stark contrast to the income of $609,677 reported in the same quarter of 2025.

For the six months ended June 30, 2026, Cardiff reported total revenue of $4.38 million, down 23.2% from $5.70 million in the first half of 2025. The net loss for this period was $5.57 million, significantly higher than the $1.68 million loss recorded in the prior year. The increase in losses was attributed to higher interest expenses, which reached $4.05 million, compared to $2.83 million in the previous year, alongside a derivative liability loss of $442,772. The company's accumulated deficit now stands at $85.62 million.

Operationally, Cardiff continues to focus on its healthcare segment, primarily through its subsidiary Nova Ortho and Spine, which provides orthopedic services. The company has also been active in restructuring its capital, including the issuance of convertible notes and common stock to manage cash flow. As of June 30, 2026, Cardiff had $217,654 in cash, down from $318,535 at the end of 2025, and reported negative cash flow from operations of $668,649 for the first half of 2026.

Looking ahead, Cardiff's management expressed concerns regarding the company's ability to continue as a going concern, citing the need for additional capital to fund operations and pursue growth opportunities. The company is exploring potential investments and believes that raising capital will be crucial for addressing cash flow shortfalls. However, there is no assurance that sufficient capital can be obtained in a timely manner or on favorable terms, which could impact the company's operational plans and financial stability.